𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

✍ Scribed by D. Roulot; V. Bourcier; V. Grando; P. Deny; Y. Baazia; H. Fontaine; F. Bailly; L. Castera; V. De Ledinghen; P. Marcellin; R. Poupon; M. Bourlière; J. P. Zarski; F. Roudot-Thoraval; The Observational VHC4 Study Group

Book ID
108885976
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
473 KB
Volume
14
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of response to peginterferon-
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b
✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v

Predictors of viral kinetics to peginter
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor of treatment efficacy, but the underlying mechanisms of the different viral kinetics to treatment are sti

Treatment extension to 72 weeks of pegin
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders
✍ Brian L. Pearlman; Carole Ehleben; Sophia Saifee 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

In hepatitis C virus (HCV) genotype 1 infection, the duration of interferon-based therapy is a critical determinant in achieving sustained virologic response (SVR). Slow or late responders to peginterferon and ribavirin may benefit from an extended treatment course. We sought to determine if therapy